Renovo Group plc (Renovo) is a United Kingdom-based biopharmaceutical product company engaged in the development of a portfolio of drugs, which exploit different mechanisms of action to reduce scarring at multiple body sites. The Company has three drugs in clinical development. Juvista in Phase III trials is used for the reduction of scarring in the skin. Zesteem in Phase III trials is used to accelerate healing (re-epithelialisation) following surgery or wounding. Prevascar is a therapeutic formulation of human recombinant Interleukin 10 (IL–10) and is a modulator of the inflammatory response. The Company’s subsidiaries include Renovo Limited and Renovo Technologies Limited.